Insider Buying: Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Purchases $264,672.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee bought 16,542 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $264,672.00. Following the completion of the purchase, the chief executive officer now owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. The trade was a 1.12 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Aardvark Therapeutics Stock Performance

AARD stock opened at $14.02 on Friday. Aardvark Therapeutics, Inc. has a 12 month low of $11.55 and a 12 month high of $19.58.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.